BR0015025A - Solução oral contendo galantamina e um agente adoçante - Google Patents

Solução oral contendo galantamina e um agente adoçante

Info

Publication number
BR0015025A
BR0015025A BR0015025-8A BR0015025A BR0015025A BR 0015025 A BR0015025 A BR 0015025A BR 0015025 A BR0015025 A BR 0015025A BR 0015025 A BR0015025 A BR 0015025A
Authority
BR
Brazil
Prior art keywords
oral solution
sweetening agent
solution containing
galantamine
containing galantamine
Prior art date
Application number
BR0015025-8A
Other languages
English (en)
Inventor
Marc Karel Jozef Francois
Tony Mathilde Jozef Kempen
Eddy Andre Josee De Proost
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR0015025A publication Critical patent/BR0015025A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

"SOLUçãO ORAL CONTENDO GALANTAMINA E UM AGENTE ADOçANTE". A presente invenção refere-se a uma solução oral compreendendo galantamina ou um sal de adição farmaceuticamente aceitável da mesma e um agente adoçante; a invenção também se refere ao uso da dita solução oral e processo de preparação da mesma.
BR0015025-8A 1999-10-26 2000-10-16 Solução oral contendo galantamina e um agente adoçante BR0015025A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99203512 1999-10-26
PCT/EP2000/010203 WO2001030318A1 (en) 1999-10-26 2000-10-16 Oral solution containing galanthamine and a sweetening agent

Publications (1)

Publication Number Publication Date
BR0015025A true BR0015025A (pt) 2002-06-18

Family

ID=8240778

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0015025-8A BR0015025A (pt) 1999-10-26 2000-10-16 Solução oral contendo galantamina e um agente adoçante

Country Status (30)

Country Link
EP (1) EP1237539B1 (pt)
JP (1) JP2003512415A (pt)
KR (1) KR100502391B1 (pt)
CN (1) CN1200691C (pt)
AR (1) AR026243A1 (pt)
AT (1) ATE306904T1 (pt)
AU (1) AU780826C (pt)
BG (1) BG65792B1 (pt)
BR (1) BR0015025A (pt)
CA (1) CA2388830C (pt)
CZ (1) CZ301996B6 (pt)
DE (1) DE60023341T2 (pt)
DK (1) DK1237539T3 (pt)
EA (1) EA005683B1 (pt)
EE (1) EE05230B1 (pt)
ES (1) ES2250211T3 (pt)
HK (1) HK1049619A1 (pt)
HR (1) HRP20020332B1 (pt)
HU (1) HUP0203484A3 (pt)
IL (2) IL149310A0 (pt)
IS (1) IS2628B (pt)
MX (1) MXPA02004149A (pt)
NO (1) NO332096B1 (pt)
PL (1) PL201694B1 (pt)
SI (1) SI1237539T1 (pt)
SK (1) SK285643B6 (pt)
TW (1) TW592725B (pt)
UA (1) UA76095C2 (pt)
WO (1) WO2001030318A1 (pt)
ZA (1) ZA200203313B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030162770A1 (en) * 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
CA2535613A1 (en) * 2003-08-13 2005-02-24 Janssen Pharmaceutica, N.V. Treatment of sleep disorders with cholinesterase inhibitors
CA2551946A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Immediate, controlled and sustained release formulations of galantamine
US8709521B2 (en) * 2007-05-22 2014-04-29 The Coca-Cola Company Sweetener compositions having enhanced sweetness and improved temporal and/or flavor profiles
DK2667715T3 (en) * 2011-01-27 2017-10-23 Neuren Pharmaceuticals Ltd TREATMENT OF AUTISM SPECTRUM DISORDERS USING GLYCYL-L-2-METHYLPROLYL-L-GLUTAMIC ACID
US20140107130A1 (en) * 2012-10-11 2014-04-17 Antrim Pharmaceuticals, LLC Oral Solution Formulations of Aripiprazole
JP6457582B2 (ja) * 2017-04-14 2019-01-23 エルメッド エーザイ株式会社 ガランタミン含有医薬組成物、並びに医薬組成物におけるガランタミンの苦味抑制方法、及びガランタミンの苦味抑制剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4010079A1 (de) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
US5272137A (en) * 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
US6323195B1 (en) * 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
JPH10273435A (ja) * 1997-01-29 1998-10-13 Fujisawa Pharmaceut Co Ltd 内服用液剤

Also Published As

Publication number Publication date
MXPA02004149A (es) 2002-10-17
AU1384901A (en) 2001-05-08
NO332096B1 (no) 2012-06-18
KR20020026010A (ko) 2002-04-04
EE05230B1 (et) 2009-12-15
AU780826C (en) 2006-02-16
NO20022003L (no) 2002-06-18
HUP0203484A2 (hu) 2003-02-28
CN1200691C (zh) 2005-05-11
DE60023341T2 (de) 2006-07-27
EA200200486A1 (ru) 2002-10-31
EP1237539A1 (en) 2002-09-11
SI1237539T1 (sl) 2006-04-30
CZ301996B6 (cs) 2010-09-01
IS6291A (is) 2002-02-28
AU780826B2 (en) 2005-04-21
JP2003512415A (ja) 2003-04-02
PL201694B1 (pl) 2009-04-30
IL149310A (en) 2006-12-10
EA005683B1 (ru) 2005-04-28
PL362849A1 (en) 2004-11-02
SK5302002A3 (en) 2002-10-08
CA2388830A1 (en) 2001-05-03
EE200200213A (et) 2003-06-16
EP1237539B1 (en) 2005-10-19
HRP20020332A2 (en) 2004-02-29
HK1049619A1 (en) 2003-05-23
ES2250211T3 (es) 2006-04-16
IL149310A0 (en) 2002-11-10
UA76095C2 (en) 2006-07-17
HUP0203484A3 (en) 2004-12-28
CN1382037A (zh) 2002-11-27
ZA200203313B (en) 2003-11-26
AR026243A1 (es) 2003-02-05
TW592725B (en) 2004-06-21
SK285643B6 (sk) 2007-05-03
DE60023341D1 (de) 2006-03-02
BG65792B1 (bg) 2009-12-31
IS2628B (is) 2010-05-15
KR100502391B1 (ko) 2005-07-19
NO20022003D0 (no) 2002-04-26
CZ20021329A3 (cs) 2002-08-14
WO2001030318A1 (en) 2001-05-03
BG106534A (en) 2002-12-29
HRP20020332B1 (en) 2011-02-28
DK1237539T3 (da) 2006-02-27
ATE306904T1 (de) 2005-11-15
CA2388830C (en) 2006-09-19

Similar Documents

Publication Publication Date Title
EE200100495A (et) Sahhariidijääkidega asendatud 1,4-bensotiasepiin-1,1-dioksiidi derivaadid, meetod nende valmistamiseks, ühendite kasutamine ning neid sisaldav ravim
CA2304704A1 (en) Formulations and methods for reducing toxicity of antineoplastic agents
TNSN97015A1 (fr) Nouveaux derives de 19-nor-pregnene.
DK275488D0 (da) Indolonderivater
BR9809468A (pt) Formulações farmacêuticas contendo voriconazol
BR0014939A (pt) Oligossacarìdeos, processo de preparação de oligossacarìdeos, composições farmacêuticas, e, utilização de oligossacarìdeos
NO20002686L (no) Forbedring av Peyronies sykdom
PT992509E (pt) Novos derivados macrolidos
EA199801028A1 (ru) Применение производных п-аминофенола для проготовления фармацевтических композиций, используемых при лечении нейродегенеративных заболеваний
BR0015025A (pt) Solução oral contendo galantamina e um agente adoçante
HK1029937A1 (en) Use of phanquinone for the treatment of alzheimer s disease.
BR0011845A (pt) Complexo farmacêutico
BR0112338A (pt) Composto, composição farmacêutica, e, uso de um composto
AP9801235A0 (en) Erythromycin derivatives.
AU6519596A (en) Use of allylamine derivatives such as terbinafine, in the manufacture of a medicament for the treatment of helicobacter pylori infection of associated diseases
HUP0103149A3 (en) Pharmaceutical composition for treatment of alzheimer's disease
MXPA99003849A (es) Derivados 9a, 11b-deshidro de 9-oxima-3-ceto-6-0-metileritromicina.
ES2179115T3 (es) Formulaciones de estramustina con propiedades farmaceuticas mejoradas.
AU2001246518A1 (en) A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease
UA3247S (uk) Упаковка медичного препарату "клофелін"
IT1309447B1 (it) Strumento chirurgico per l'estrazione dei denti.
MY134931A (en) Oral galantamine solution
TH15815A (th) การใช้อนุพันธ์เพรคเนม
UA1954S (uk) Упаковка медичного препарату "димексид"
UA1958S (uk) Упаковка медичного препарату "аспаркам"

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O E 13 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.